---
title: "Qube Research & Technologies discloses net short position in Cellectis shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294219844.md"
description: "Qube Research & Technologies has disclosed a 0.5% net short position in Cellectis shares, as reported in an AMF filing."
datetime: "2026-07-29T13:58:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294219844.md)
  - [en](https://longbridge.com/en/news/294219844.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294219844.md)
generator: "portal-rs"
---

# Qube Research & Technologies discloses net short position in Cellectis shares

-   Qube Research & Technologies disclosed a 0.5% net short position in Cellectis shares, according to an AMF filing. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)

## Related News & Research

- [Cellectis S.A. (NASDAQ:CLLS) Given Average Recommendation of "Moderate Buy" by Brokerages](https://longbridge.com/en/news/298108510.md)
- [Cellectis publishes corporate presentation on allogeneic CAR-T pipeline, TALEN gene-editing platform](https://longbridge.com/en/news/295217037.md)
- [BOFH: Oh no! The CMS ate 500 pages of corporate documentation](https://longbridge.com/en/news/298702240.md)
- [Damartex reports FY2025-26 annual results release available](https://longbridge.com/en/news/298344100.md)
- [Maison Pommery & Associés files 2025 universal registration document with AMF](https://longbridge.com/en/news/298286367.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**